<DOC>
	<DOCNO>NCT00003874</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate cancer cell either kill deliver cancer-killing substance without harm normal cell . PURPOSE : Phase I/II trial study effectiveness monoclonal antibody therapy treat patient lymphoma leukemia .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Lymphoma Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate efficiency tumor cell removal immunomagnetic technique patient B cell malignancy . II . Determine toxicity mobilize peripheral blood stem cell ( PBSC ) component enrich CD34+ deplete B cell patient population . III . Compare recovery use treatment regimen use unmanipulated PBSC CD34+ PBSC component patient population . OUTLINE : Patients assign one two treatment arm chemotherapy ( chemotherapy protocol follow FHCRC-506.2 ) . Patients undergo mobilization isolation CD34+ cell describe FHCRC-506.2 . Peripheral blood stem cell collect apheresis CD34+ cell isolate use magnetic bead . Monoclonal antibody CD19 CD20 add CD34+ cell sensitize remain tumor cell . Patients undergo transplantation day 0 , accord applicable transplant protocol , one month mobilization . Some patient may receive posttransplant interleukin-2 achieve durable engraftment . Patients follow day 30 , 80 , 180 , 365 , 395 . PROJECTED ACCRUAL : A total 20-30 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent B cell malignancy positive CD19 and/or CD20 antigens Demonstrated probable tumor cell contamination peripheral blood stem cell components No CNS metastases High risk B cell malignancy indicative autologous hematopoietic stem cell transplantation No HLA match donor Eligible mobilization blood stem cell use chemotherapy GCSF Eligible transplantation protocol cover classification stage malignancy Intention proceed transplantation within 60 day peripheral blood stem cell collection PATIENT CHARACTERISTICS : Age : 70 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No active infection HIV negative Adequate organ function define mobilization transplant protocol At least 20 CD34+ cells/uL peripheral blood immunomagnetic separation PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>B-cell adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>